Therapy Detail

Therapy Name Metformin
Synonym
Therapy Description

Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR (NCI Drug Dictionary). Glucophage (metformin) is FDA approved for type 2 diabetes (FDA.gov).

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Metformin Glucophage Apo-Metformin Glucophage (metformin) inhibits part of the mitochondrial respiratory chain and may exert antineoplastic effects through inhibition of mTOR (NCI Drug Dictionary). Glucophage (metformin) is FDA approved for type 2 diabetes (FDA.gov).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
STK11 wild-type Advanced Solid Tumor sensitive Metformin Preclinical - Cell culture Actionable In a preclinical studies, Glucophage (metformin) inhibited cancer cell growth by activating the AMP kinase pathway in a variety of cancer cell lines that retained one functional allele of STK11 (PMID: 17062558, PMID: 18006825). 18006825 17062558
Unknown unknown lung cancer not applicable Metformin Preclinical - Cell culture Actionable In a preclinical study, Glucophage (metformin) inhibited proliferation of several lung cancer cell lines in culture, including squamous, adenocarcinoma, large cell, and small celll lung cancer cell lines (PMID: 22576795). 22576795
KRAS wild-type squamous cell carcinoma no benefit Metformin Preclinical - Cell line xenograft Actionable In a preclinical study, Glucophage (metformin) did not induce growth inhibition or apoptosis in a KRAS wild-type squamous cell carcinoma cell line in culture and did not inhibit tumor growth in xenograft models (PMID: 23877793). 23877793
ERBB2 positive Her2-receptor positive breast cancer predicted - sensitive Metformin Phase III Actionable In a Phase III trial, ERBB2 (HER2) positive breast cancer patients with diabetes demonstrated a greater disease free survival and overall survival when treated with Glucophage (metformin) compared to ERBB2 (HER2) positive breast cancer patients with diabetes not treated with Glucophage (metformin) (PMID: 28375706). 28375706
KRAS mutant Advanced Solid Tumor sensitive Metformin Preclinical - Cell line xenograft Actionable In a preclinical study, Glucophage (metformin) inhibited tumor growth in a variety of KRAS-mutant cancer cell line xenograft models (PMID: 23877793). 23877793
STK11 loss Advanced Solid Tumor no benefit Metformin Preclinical - Cell culture Actionable In a preclinical study, Glucophage (metformin) was unable to inhibit cancer cell growth in cancer cell lines with biallelic loss of STK11 (PMID: 17062558, PMID: 18006825). 18006825 17062558
PTEN del urinary bladder cancer sensitive Metformin Preclinical Actionable In a preclinical study, bladder cancer cells with PTEN deletion were sensitive to Glucophage (metformin) in culture, resulting in inhibition of cell growth (PMID: 26921394). 26921394
PTEN pos KRAS G12D endometrial cancer sensitive Metformin Preclinical - Cell line xenograft Actionable In a preclinical study, Glucophage (metformin) inhibited cell proliferation and induced apoptosis in a PTEN-expressing human endometrial cancer cell line harboring KRAS G12D in culture and decreased tumor growth in xenograft models (PMID: 24077915). 24077915
HRAS mutant urinary bladder cancer sensitive Metformin Preclinical Actionable In a preclinical study, mouse models of bladder cancer harboring an HRAS mutation were sensitive to Glucophage (metformin), resulting in tumor growth reduction and prevention of hyperplasia regression (PMID: 26921394). 26921394
Unknown unknown head and neck squamous cell carcinoma not applicable Metformin Clinical Study Actionable In a meta-analysis, Glucophage (metformin) treatment decreased recurrence and metastasis and improved overall survival of head and neck squamous cell carcinoma patients (PMID: 25636350). 25636350
Unknown unknown Indication other than cancer not applicable Metformin FDA approved Actionable Glucophage (metformin) is FDA approved for use in patients with type-2 diabetes (FDA.gov). detail...
Unknown unknown prostate cancer not applicable Metformin Phase II Actionable In a Phase II trial, Glucophage (metformin) demonstrated safety and preliminary efficacy in patients with castration-resistant prostate cancer (PMID: 24412228). 24412228
Unknown unknown non-small cell lung carcinoma not applicable Metformin Preclinical - Cell culture Actionable In a preclinical study, Glucophage (metformin) inhibited proliferation and induced cell-cycle arrest and apoptosis in non-small cell lung cancer cell lines in culture, independent of STK11 (LKB1) status (PMID: 26847819). 26847819
Unknown unknown pancreatic cancer no benefit Metformin Preclinical - Pdx Actionable In a preclinical study, long term treatment (28 days) of Glucophage (metformin) did not result in decreased tumor growth in patient-derived pancreatic cancer xenograft models (PMID: 26760500). 26760500
IDH1 R132H colorectal cancer sensitive Metformin Preclinical Actionable In a preclinical study, colorectal carcinoma cells expressing IDH1 R132H were sensitive to Glucophage (metformin), resulting in decreased cell proliferation in culture (PMID: 26363012). 26363012
Unknown unknown breast cancer not applicable Metformin Preclinical - Cell line xenograft Actionable In a preclinical study, Glucophage (metformin) inhibited the growth of a breast cancer cell line in culture and resulted in decreased tumor volume in a cell line xenograft model (PMID: 26351208). 26351208
Clinical Trial Phase Therapies Title Recruitment Status
NCT03053544 Phase II Metformin Metformin With Neoadjuvant Chemoradiation to Improve Pathologic Responses in Rectal Cancer Active, not recruiting
NCT02019979 Phase II Metformin Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC) (METRO) Terminated
NCT02420652 Phase II Metformin Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy Active, not recruiting
NCT02780024 Phase II Metformin Metformin, Neo-adjuvant Temozolomide and Hypo- Accelerated Radiotherapy Followed by Adjuvant TMZ in Patients With GBM Recruiting
NCT01579812 Phase II Metformin Evaluation of Metformin, Targeting Cancer Stem Cells for Prevention of Relapse in Gynecologic Patients Completed
NCT01981525 Metformin A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome Completed
NCT01422746 Metformin Dexamethasone Effect of Metformin on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess Recruiting
NCT01302379 Phase I Metformin Reach for Health Study: Obesity-related Mechanisms and Mortality in Breast Cancer Survivors Unknown status
NCT01324180 Phase I Metformin Dexamethasone + Doxorubicin + Pegaspargase + Vincristine Vincristine, Dexamethasone, Doxorubicin, and PEG-asparaginase (VPLD) and Metformin for Relapsed Childhood Acute Lymphoblastic Leukemia (ALL) Completed
NCT02176161 Phase II Metformin Metformin Prostate Cancer Adjuvant Trial Recruiting
NCT02531308 Phase II Metformin Cyclophosphamide + Doxorubicin + Prednisone + Vincristine Pegfilgrastim Rituximab Metformin in Combination With Standard Induction Therapy for Large B-cell Lymphoma (DLBCL) Terminated
NCT01717482 Phase II Metformin Metformin as a Chemoprevention Agent in Non-small Cell Lung Cancer Active, not recruiting
NCT02815397 Phase II Metformin DA-EPOCH-Rituximab/Metformin (RM) for Double Hit Lymphoma Terminated
NCT02153450 Phase I Metformin Stereotactic Radiosurgery and Metformin Hydrochloride in Treating Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer Active, not recruiting
NCT01488552 Phase Ib/II Oxaliplatin Fluorouracil + Irinotecan + Leucovorin Gemcitabine + Nab-paclitaxel Metformin Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer Completed
NCT03109873 Phase I Metformin Metformin Hydrochloride in Affecting Cytokines and Exosomes in Patients With Head and Neck Cancer Active, not recruiting
NCT01578551 Phase II Metformin Carboplatin + Paclitaxel Bevacizumab A Randomized Phase II Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma. Terminated
NCT01697566 Phase III Metformin An Endometrial Cancer Chemoprevention Study of Metformin Active, not recruiting
NCT01340300 Phase II Metformin Exercise and Metformin in Colorectal and Breast Cancer Survivors Completed
NCT02035787 Phase I Metformin Metformin With the Levonorgestrel-Releasing Intrauterine Device for the Treatment of Complex Atypical Hyperplasia (CAH) and Endometrial Cancer (EC) in Non-surgical Patients Recruiting
NCT01620593 Phase II Metformin Castration Compared to Castration Plus Metformin as First Line Treatment for Patients With Advanced Prostate Cancer Completed
NCT01954732 Phase I Metformin Metformin Hydrochloride in Treating Patients With Pancreatic Cancer That Can be Removed by Surgery Withdrawn
NCT02042495 Phase II Metformin Endometrial Cancer Biomarker Changes Following Exposure to Metformin Withdrawn
NCT01528046 Phase I Metformin Irinotecan + Temozolomide + Vincristine Metformin in Children With Relapsed or Refractory Solid Tumors Recruiting
NCT02614859 Phase II Bicalutamide Metformin Bicalutamide With or Without Metformin for Biochemical Recurrence in Overweight or Obese Prostate Cancer Patients Recruiting
NCT02278965 Phase I Metformin Metformin and Omega-3 Fatty Acids in Woman With a History of Early Stage Breast Cancer Active, not recruiting
NCT01666730 Phase II Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Metformin Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer Completed
NCT02040376 Phase III Metformin Placebo Controlled Double Blind Crossover Trial of Metformin for Brain Repair in Children With Cranial-Spinal Radiation for Medulloblastoma Completed
NCT02186847 Phase II Metformin Carboplatin + Paclitaxel Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer Active, not recruiting
NCT02083692 Metformin Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling Completed
NCT01877564 Phase II Metformin A Randomized Pilot Study to Evaluate the Effects of a Short Course of Metformin Versus No Therapy in the Period Prior to Hysterectomy for Grade 1-2 Adenocarcinoma of the Endometrium in Obese Non-Diabetic Women Completed
NCT02394652 Phase II Cisplatin Metformin The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer Recruiting
NCT02402348 Phase I Metformin Pilot Study of Metformin in HNSCC to Investigate the Effects of MF, Tumor Genotype and MF-genotype Interactions, on Tumor Metabolism and Anoikis Terminated
NCT02048384 Phase Ib/II Metformin + Sirolimus Metformin A Study of Metformin With or Without Rapamycin as Maintenance Therapy After Induction Chemotherapy in Subjects With Pancreatic Cancer Active, not recruiting
NCT01996696 Phase II Metformin A Study With or Without Metformin to Determine if Metformin Can Prevent Weight Gain and Other Problems (i.e. Diabetes, Increased Cholesterol, Etc.) That Can Arise From the Use of Hormonal Therapy in Combination With Radiation Therapy When Treating Aggressive Localized Prostate Cancer. Recruiting
NCT02978547 Phase II Metformin The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma (Metformin 001) Not yet recruiting
NCT01310231 Phase II Metformin A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer Completed
NCT02115464 Phase II Metformin Advanced Lung Cancer Treatment With Metformin and Chemo-Radiotherapy Active, not recruiting
NCT02122185 Phase II Metformin Carboplatin + Docetaxel + Paclitaxel Metformin Hydrochloride and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting
NCT02376166 Phase I Metformin Metformin for Rising PSA Remote Trial Completed
NCT01793948 Phase I Metformin Metformin Hydrochloride vs. Placebo in Overweight or Obese Patients at Elevated Risk for Breast Cancer Completed
NCT03086733 Phase II Metformin Phase II Lung Metcore - Preoperative Metformin for Lung Cancer (Metcore) Recruiting
NCT01430351 Phase I Temozolomide Memantine Metformin Mefloquine Phase I Factorial Trial of Temozolomide, Memantine, Mefloquine, and Metformin for Post-Radiation Therapy (RT) Glioblastoma Multiforme (GBM) Active, not recruiting
NCT01797523 Phase II Letrozole Everolimus Metformin RAD/Letrozole/Metformin Active, not recruiting
NCT02437812 Phase II Paclitaxel Carboplatin Metformin Study of Paclitaxel, Carboplatin and Oral Metformin in the Treatment of Advanced Stage Ovarian Carcinoma Recruiting
NCT03477162 Phase 0 Metformin Metformin Pharmacology in Human Cancers: A Proof of Principle Study Recruiting
NCT03076281 Phase II Doxycycline Doxycycline + Metformin Metformin Metformin Hydrochloride and Doxycycline in Treating Patients With Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery Active, not recruiting
NCT01750567 Phase II Metformin A Pilot Study of Metformin Therapy in Patients With Relapsed Chronic Lymphocytic Leukemia (CLL) and Untreated CLL Recruiting
NCT01864096 Phase III Metformin The Metformin Active Surveillance Trial (MAST) Study Recruiting
NCT02285855 Phase II Metformin Metformin in Non Small Cell Lung Cancer (NSCLC) Terminated